Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors

SAN DIEGO, June 4, 2020/ PRNewswire/– Medical Cannabis, Inc.( OTC: MJNA) (the “Company”), the first-ever publicly traded marijuana business in the United States that launched the world’s first-ever cannabis-derived nutraceutical items, brand names and supply chain, announced today that its investment company Kannalife, Inc.(” Kannalife”) (OTCQB: KLFE) has appointed biotechnology and pharmaceutical market veteran Terrence O. Tormey to the company’s Board of Advisors.

” Kannalife continues to prove itself as a leader in cannabinoid research study and its reputation to include well-respected biotech and pharmaceutical leaders like Terrence Tormey to its group amplifies its efforts,” said Medical Cannabis, Inc. CEO Dr. Stuart Titus

” It’s an honor to have Terry join our board of advisers since his experience, vision and knowledge in the life sciences industry will help us begin to design our commercialization and distribution prepare for Atopidine ™,” said Dean Petkanas, CEO of Kannalife.

Mr. Tormey brings over 4 years of experience in the life sciences market and has held many C-Level management positions, board seats, and has actually led effective sales and marketing campaigns with popular business including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson). Most recently he was the CEO of Kibow Biotech, a company involved in the development of novel kidney care treatment for persistent kidney disease.

” I am honored to serve as a consultant to Kannalife.

About Medical Marijuana, Inc.
We are a business of firsts ® Medical Marijuana, Inc.( MJNA) is a marijuana business with three unique organisation units in the non-psychoactive cannabinoid area: an international portfolio of cannabinoid-based nutraceutical brands led by Kannaway ® and HempMeds ® ; a leader in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based scientific research study and botanical drug advancement sector led by its pharmaceutical investment firm and partners including AXIM ® Biotechnologies, Inc and Kannalife, Inc Medical Cannabis, Inc. was called a leading CBD manufacturer by CNBC Medical Cannabis, Inc. was also the first company to receive historical import permits for CBD items from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the advancement of global markets. The company’s flagship item Real Scientific Hemp Oil has been used in several effective scientific research studies throughout Mexico and Brazil to understand its security and efficacy.

Medical Marijuana, Inc.’s head office remains in San Diego, California, and additional information is available at OTCMarkets.com or by going to www.medicalmarijuanainc.com To see Medical Marijuana, Inc.’s business video, click on this link

Investors and consumers are likewise encouraged to buy CBD oil and other items at Medical Cannabis, Inc.’s store.

About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical medchem business concentrated on the advancement of exclusive and trademarked book, monotherapeutic particles for clients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a persistent neuropathy triggered by toxic chemotherapeutic representatives; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder brought on by excessive concentrations of ammonia and ethanol in the brain; mild distressing brain injury (mTBI), a condition related to single and repetitive impact injuries; and chronic distressing encephalopathy (CTE), a disease connected with highly recurring effect injuries in professional and amateur sports.

Atopidine ™ is Kannalife’s novel, patented little particle that has actually been shown to have protective and anti-inflammatory residential or commercial properties in pre-clinical screening. The same research studies show that it has actually also outshined cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalife’s leading patented, investigational, unique, monotherapeutic item for the potential treatment of a range of neurodegenerative and neuropathic discomfort conditions, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have actually been reviewed or approved for client usage by the U.S. Food and Drug Administration (FDA) or any other health care authority in the world. Their safety and efficacy have not been verified by FDA-approved research study.

The Business’s KLS Family of exclusive molecules focuses on dealing with oxidative stress-related illness such as HE, persistent discomfort from neuropathies like CIPN, and neurodegenerative illness like CTE. Kannalife conducts its research study and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit www.kannalife.com and go to the Company’s Twitter page at @Kannalife

FORWARD-LOOKING DISCLAIMER
This press release may include certain forward-looking statements and information, as specified within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934, and goes through the Safe Harbor developed by those sections. This material includes statements about expected future occasions and/or monetary outcomes that are forward-looking in nature and topic to dangers and uncertainties. Such forward-looking declarations by definition include dangers, unpredictabilities and other elements, which might trigger the actual outcomes, performance or achievements of Medical Marijuana, Inc. to be materially various from the declarations made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been assessed by the Food and Drug Administration. This item is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Cannabis, Inc. does not sell or disperse any products that remain in violation of the United States Controlled Substances Act.

CONTACT:
Public Relations Contact:
Andrew Hard
President
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

Financier Relations Contact:
P. (858) 283-4016
[email protected]

SOURCE Medical Marijuana, Inc.